DSIP

Overview

DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide isolated in 1977 by Schoenenberger and colleagues in Basel. It was discovered as the substance that induced delta sleep after intravenous infusion of blood dialysate from sleeping rabbits. That discovery opened a field of research into the neurobiology of sleep and stress.

DSIP's profile extends beyond sleep induction. In the published literature it has been studied in the context of stress response, circadian rhythm, mitochondrial function, and neuromodulation. The peptide has been detected in human plasma, CSF, urine, and breast milk, bound to a carrier protein. That points to a physiological role as an endogenous neuromodulator.

At the same time, it is scientifically honest to say that the mechanism is largely unresolved. The DSIP gene, its corresponding protein, and a possible receptor have never been isolated, and the original sleep hypothesis is regarded in the literature as weakly supported. It is one of the older, most enigmatic neuropeptides in this field.

The available evidence base is predominantly preclinical and concentrated in specific research groups, largely Russian. Controlled human intervention studies are absent. The physiological presence in humans offers an interesting starting point, but is not evidence of effect.

Mechanism of action

The proposed mechanisms of action of DSIP derive from preclinical research and are not fully resolved. A specific receptor has never been identified.

Sleep and circadian rhythm

• Associated with delta-sleep induction in early animal models, though the effect proved species-specific and has not been consistently replicated
• Influences the circadian locomotor rhythm in animal models under chronic administration
• Linked in early research to MAO-A activity and RNA synthesis in the brain

Stress modulation via the limbic system

• In animal models, reduces Fos expression in the paraventricular nucleus and limbic structures after emotional stress
• Influences substance P, beta-endorphin, and corticosterone in the stress response
• The effect varies with the animal's individual stress resistance

Mitochondrial function

• In isolated rat brain mitochondria, DSIP increased the phosphorylated respiration rate (V3) and the respiratory control ratio
• With pretreatment, one study counteracted the hypoxia-induced decline in mitochondrial respiratory activity
• Part of this work used Deltaran, a glycine-DSIP formulation, alongside pure DSIP

Research findings

• In isolated rat brain mitochondria, DSIP increased the V3 respiration rate and the respiratory control ratio, and improved the efficiency of ADP phosphorylation
• With pretreatment, the hypoxia-induced decline in mitochondrial respiratory activity was counteracted (partly using the Deltaran formulation)
• In animal models, DSIP reduced limbic Fos expression after emotional stress and modulated the neurohormonal stress response (substance P, beta-endorphin, corticosterone)
• In a liver-tissue study under stress, DSIP showed dose-dependent, non-linear protection of antioxidant enzyme systems; the effect disappeared at the highest dose
• In a more recent study, intranasal DSIP accelerated motor recovery after experimental stroke in rats; the difference in infarct volume was not significant
• DSIP and phosphorylated DSIP (DSIP-P) have been detected in human plasma, CSF, urine, and breast milk; endogenous DSIP is bound to a carrier protein and thereby protected from proteolysis

Mitochondrial and molecular findings (preclinical)

• Increased V3 respiration rate and respiratory control ratio in isolated rat brain mitochondria
• Improved efficiency of ADP phosphorylation
• Counteraction of hypoxia-induced mitochondrial dysfunction with pretreatment (partly with Deltaran)

Animal-model findings

• Reduced limbic Fos expression after emotional stress
• Modulation of the neurohormonal stress response (substance P, beta-endorphin, corticosterone)
• Protection of antioxidant enzyme systems in liver tissue under stress (dose-dependent, non-linear: the effect disappeared at the highest dose)
• Intranasal DSIP accelerated motor recovery after experimental stroke in rats; the difference in infarct volume was not significant

Human physiological data

• DSIP and DSIP-P have been detected in human plasma, CSF, urine, and breast milk
• Endogenous DSIP is bound to a carrier protein and thereby protected from proteolysis
• There are no controlled human intervention studies

Research context

DSIP has a long research history of more than four decades and hundreds of publications, but that volume mainly reflects historical interest from the 1980s, not current strength of evidence. Much of the work is old, originates from a limited number of groups, and has not been independently replicated.

Most strikingly, the central mechanism has never been resolved. An authoritative review describes DSIP as a "still unresolved riddle": the sleep hypothesis is weakly supported, and the gene, protein, and receptor have never been isolated. That makes DSIP scientifically intriguing, but places it firmly in the preclinical, exploratory phase.

The mitochondrial thread is the most distinctive part of the profile: the overlap between neuromodulation and cellular energy handling is an interesting interface. But it rests on a small number of older studies, partly using the Deltaran formulation, and deserves independent, modern replication before stronger conclusions can be drawn.

Open questions

DSIP is endogenously present in humans, but the mechanism remains unresolved and controlled human intervention data are absent. The dossier is intriguing but firmly preclinical.

• There are no controlled human intervention studies
• The central mechanism of action is unresolved; the gene, protein, and receptor have never been isolated
• The optimal dose and route of administration in humans are unknown
• The pharmacokinetic profile under exogenous administration in humans has not been characterised
• Much of the research is concentrated in a limited, largely Russian research tradition; international replication is limited
• The long-term safety profile in humans has not been established

Research outlook

Modern, independent replication of the mitochondrial and stress-protective findings, using pure DSIP and standardised methods

Sleep research with modern polysomnographic methods to test or refute the original hypothesis

Resolution of the mechanism of action: identification of a possible receptor or binding site

Research into its role in stress resilience as a defined research domain

Scientific interest

Endogenous neuromodulation and the biology of sleep.

Stress modulation via limbic circuits.

Mitochondrial function and protection under hypoxia: a distinctive interface.

A historical riddle: an endogenous peptide with a still-unresolved mechanism.

Specifications

References

1. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). · Schoenenberger GA. · European Neurology · 1984
2. Delta-sleep inducing peptide sequels in the mechanisms of resistance to emotional stress. · Sudakov KV, Coghlan JP, Kotov AV, et al. · Annals of the New York Academy of Sciences · 1995
3. Delta-sleep inducing peptide (DSIP) and ACTH (4-10) analogue influence fos-induction in the limbic structures of the rat brain under emotional stress. · Sudakov KV, Umriukhin PE, Koplik EV, Anokhin KV. · Stress · 2001
4. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. · Khvatova EM, Samartzev VN, Zagoskin PP, et al. · Peptides · 2003
5. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. · Kovalzon VM, Strekalova TV. · Journal of Neurochemistry · 2006
6. Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress. · Bobyntsev II, Kryukov AA, Belykh AE, Dudka VT. · Bulletin of Experimental Biology and Medicine · 2016
7. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. · Tukhovskaya EA, Shaykhutdinova ER, Pakhomova IA, et al. · Molecules · 2021

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished